Rid­ing a wave of pos­i­tive PhI­II read­outs, Pfiz­er gets a snap re­view for lung can­cer drug da­comi­tinib

Pfiz­er’s de­ci­sion to hand over four years of work on a port­fo­lio of off-the-shelf CAR-T drugs doesn’t mean that they’re any less fo­cused on their all-im­por­tant late-stage on­col­o­gy pipeline. And the FDA helped make that ap­par­ent to­day by hand­ing the phar­ma gi­ant a fast-tracked pri­or­i­ty re­view for da­comi­tinib — one of their top late-stage can­cer drugs in line for an ini­tial ap­proval lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER